Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Website: jnj.com


  • Good financial results growth rate 17.6% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (6.2%)
  • Dividend yield for the last twelve months 3.4%
  • Free cash flow yield 0.0% (LTM)
  • Share price is 0.6% higher than minimum and 22.3% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (12.4x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: JNJ
Share price, USD:  (+0.6%)144.47
year average price 155.94  


year start price 155.46 2023-12-23

max close price 167.38 2024-09-10

min close price 143.58 2024-12-19

current price 144.47 2024-12-21
Common stocks: 2 631 399 832

Dividend Yield:  3.4%
EV / LTM EBITDA: 12.4x
EV / EBITDA annualized: 7.4x
Last revenue growth (y/y):  -12.1%
Last growth of EBITDA (y/y):  +47.4%
Historical revenue growth:  -0.4%
Historical growth of EBITDA:  +12.9%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 380 158
Net Debt ($m): 32 590
EV (Enterprise Value): 412 748
EBITDA LTM ($m): 33 156
EV / LTM EBITDA: 12.4x
Price to Book: 5.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-12-19seekingalpha.com

Johnson & Johnson: Dividend Legend At A Discount

2024-12-18globenewswire.com

Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA® (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplant

2024-12-16zacks.com

Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors

2024-12-16reuters.com

US FDA declines to approve injection form of J&J's lung cancer drug

2024-12-10247wallst.com

Johnson & Johnson Just Paid Investors: Here's How Much They Received

2024-12-09prnewswire.com

CARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study

2024-12-09globenewswire.com

NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer

2024-12-08prnewswire.com

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma

2024-12-08prnewswire.com

TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma

2024-12-08prnewswire.com

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data